MetLife SEC Filings

MetLife, Inc. declared quarterly dividends on its preferred stock, providing cash income to holders of its Series A, Series E and Series F securities. The Series A floating rate non-cumulative preferred stock will pay a quarterly dividend of $0.33489390 per share. The 5.625% non-cumulative preferred stock, Series E, will pay $351.5625 per share, or $0.3515625 per depositary share, each representing a 1/1,000th interest in a share. The 4.75% non-cumulative preferred stock, Series F, will pay $296.875 per share, or $0.296875 per depositary share, each representing a 1/1,000th interest in a share.

MetLife, Inc. reported a change in beneficial ownership. The Board of Directors, as an entity, filed an amended Schedule 13D noting beneficial ownership of 106,549,803 shares of common stock, representing 16.17% of the class as of October 31, 2025. The Board has shared voting power over 106,549,803 shares and no sole voting or dispositive power.

The shares are held by the MetLife Policyholder Trust, originally issued 494,466,664 shares in 2000 under the demutualization plan. The Trustee votes per Board recommendations on most matters; on specified Beneficiary Consent Matters, votes are cast in proportion to beneficiary instructions. Since July 31, 2025, Trust holdings decreased from 108,242,821 to 106,549,803 due to beneficiary transactions and withdrawals under the Plan and Trust Agreement. Beneficiaries have rights to dividends and sale proceeds on their allocated shares.

MetLife, Inc. furnished investor materials for the quarter ended September 30, 2025. The company provided an Earnings Release (Exhibit 99.1), a Quarterly Financial Supplement (Exhibit 99.2), a Total AUM Fact Sheet (Exhibit 99.3), and Supplemental Slides (Exhibit 99.4). These materials are furnished, not filed, and summarize quarterly results and assets under management.

MetLife (MET) reported an insider administrative transaction by its EVP & Chief Legal Officer. On 10/31/2025, 4,420 shares of common stock were withheld at $79.82 under transaction code F, which indicates shares withheld to cover taxes on restricted stock units.

After this transaction, the reporting person directly owned 10,452 shares.

MetLife, Inc. (MET) disclosed an insider equity transaction by its EVP & Chief Accounting Officer. On 10/31/2025, the officer acquired 11,902 shares of common stock, reported as directly owned after the transaction. A footnote indicates these shares relate to restricted stock units, each representing the right to receive one share of MetLife common stock.

This filing records an equity award event and updates the officer’s reported holdings; it does not reflect an open‑market purchase or sale.

The Vanguard Group filed Amendment No. 9 to Schedule 13G reporting beneficial ownership of 64,749,341 MetLife (MET) common shares, representing 9.73% of the class as of 09/30/2025.

Vanguard reports 0 shares with sole voting power and 3,353,980 with shared voting power. It has sole dispositive power over 59,193,894 shares and shared dispositive power over 5,555,447 shares. The filing identifies Vanguard as an investment adviser and certifies the holdings were acquired and are held in the ordinary course, not to change or influence control.

The filing notes that Vanguard’s clients have the right to receive dividends and sale proceeds related to the reported securities, and that no single other person’s interest exceeds 5%.

Rule 144 notice: A holder filed to sell 196 shares of common stock through Barclays on the NYSE. The filing lists an aggregate market value of $15,435 and an approximate sale date of 10/29/2025. Shares outstanding were 665,026,054.

The filer reports prior sales in the past three months by related accounts, including 333 shares on 10/01/2025 for gross proceeds of $27,282.69. This notice reflects a proposed secondary sale by an existing holder.